Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutic
(NQ:
HALO
)
61.57
+0.64 (+1.05%)
Streaming Delayed Price
Updated: 11:47 AM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halozyme Therapeutic
< Previous
1
2
3
4
5
6
7
Next >
Arcellx Stock Earns Relative Strength Rating Upgrade
June 21, 2024
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.
Via
Investor's Business Daily
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
June 20, 2024
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level.
Via
Investor's Business Daily
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
June 19, 2024
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
The 3 Best Healthcare Stocks to Buy in June 2024
June 15, 2024
Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on.
Via
InvestorPlace
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
June 14, 2024
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas.
Via
Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
June 12, 2024
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.
Via
Investor's Business Daily
NASDAQ:HALO, a growth stock which is not overvalued.
June 04, 2024
NASDAQ:HALO stands out as a growth opportunity that won't break the bank.
Via
Chartmill
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
May 14, 2024
Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.
Via
Chartmill
Expert Ratings For Halozyme Therapeutics
May 07, 2024
Via
Benzinga
Krystal Biotech Stock Sees RS Rating Jump To 91
June 11, 2024
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88.
Via
Investor's Business Daily
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
June 09, 2024
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.
Via
Benzinga
Halozyme Therapeutics Scores RS Rating Jump To 91
June 07, 2024
On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91.
Via
Investor's Business Daily
This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
June 07, 2024
Via
Benzinga
Halozyme Therapeutics +13% On Thursday: What's Going On?
June 06, 2024
Halozyme Therapeutics surges as it raises FY24 guidance, driven by increased revenue projections and a new European patent for its drug delivery platform.
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout.
April 30, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): a strong growth stock preparing for the next leg up?.
Via
Chartmill
NASDAQ:HALO is not too expensive for the growth it is showing.
April 23, 2024
NASDAQ:HALO stands out as a growth opportunity that won't break the bank.
Via
Chartmill
9 Analysts Have This To Say About Halozyme Therapeutics
April 16, 2024
Via
Benzinga
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 06, 2024
Via
Benzinga
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday
June 06, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 8 Analysts
June 04, 2024
Via
Benzinga
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
May 29, 2024
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
May 16, 2024
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
May 14, 2024
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.
Via
Investor's Business Daily
The 3 Best Biotech Stocks to Buy in May 2024
May 09, 2024
If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.
Via
InvestorPlace
When you look at NASDAQ:HALO, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
May 08, 2024
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 07, 2024
HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
May 01, 2024
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72.
Via
Investor's Business Daily
Sarepta Therapeutics Stock Shows Improved Technical Strength
April 29, 2024
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73.
Via
Investor's Business Daily
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
April 25, 2024
Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now.
Via
InvestorPlace
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
April 16, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.